An update on pharmacotherapy of autism spectrum disorder in children and adolescents

References

• Adams, J. B., Audhya, T., McDonough-Means, S., Rubin, R. A., Quig, D., Geis, E., … Lee, W. (2011). Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatrics, 11, 111. doi:10.1186/1471-2431-11-111
   PubMed Web of Science ®Google Scholar
• Aman, M. G., Findling, R. L., Hardan, A. Y., Hendren, R. L., Melmed, R. D., Kehinde-Nelson, O., … Katz, E. (2017). Safety and efficacy of memantine in children with autism: Randomized, placebo-controlled study and open-label extension. Journal of Child and Adolescent Psychopharmacology, 27, 403–412. doi:10.1089/cap.2015.0146
   PubMed Web of Science ®Google Scholar
• Aman, M. G., Mcdougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., … Wagner, A. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry, 48, 1143–1154. doi:10.1097/CHI.0b013e3181bfd669
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). (2013). Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Assoc.
   Google Scholar
• Anagnostou, E., Brian, J. A., Campo-Soria, C., Capano, L., Esler, A. N., Hudock, R., … Jacob, S. (2017). A randomized controlled trial of intranasal oxytocin in autism spectrum disorder. Oral presentation at the International Meeting for Autism Research (IMFAR), San Francisco.
   Google Scholar
• Anderson, G. M., Scahill, L., McCracken, J. T., McDougle, C. J., Aman, M. G., Tierney, E., … Vitiello, B. (2007). Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biological Psychiatry, 61, 545–550. doi:10.1016/j.biopsych.2006.02.032
   PubMed Web of Science ®Google Scholar
• Anderson, L. T., Campbell, L., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195–1202. doi:10.1176/ajp.141.10.1195
   PubMed Web of Science ®Google Scholar
• Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19, 227–239. doi:10.1007/BF02211843
   PubMed Web of Science ®Google Scholar
• Autism Speaks press release. (2009, February 18). Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA): first industry-sponsored trial for the Autism Clinical Trials Network (ACTN). Retrieved from http://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia
   Google Scholar
• Bakermans-Kranenburg, M. J., & Van IJzendoorn, M. H. (2013). Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Translational Psychiatry, 3, e258. doi:10.1038/tp.2013.34
   PubMed Web of Science ®Google Scholar
• Bauman, M. L., & Kemper, T. L. (2005). Neuroanatomic observations of the brain in autism: A review and future directions. International Journal of Developmental Neuroscience, 23, 183–187. doi:10.1016/j.ijdevneu.2004.09.006
   PubMed Web of Science ®Google Scholar
• Belsito, K. M., Law, P. A., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord, 31, 175–181. doi:10.1023/A:1010799115457
   PubMed Web of Science ®Google Scholar
• Bent, S., Bertoglio, K., Ashwood, P., Bostrom, A., & Hendren, R. L. (2011). A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. Journal of Autism and Developmental Disorders, 41, 545–554. doi:10.1007/s10803-010-1078-8
   PubMed Web of Science ®Google Scholar
• Bent, S., Hendren, R. L., Zandi, T., Law, K., Choi, J., Widjaja, F., … Law, P. (2014). Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. Journal of the American Academy of Child & Adolescent Psychiatry, 53, 658–666. doi:10.1016/j.jaac.2014.01.018
   PubMed Web of Science ®Google Scholar
• Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., … Carpenter, R. L. (2017). Arbaclofen in fragile X syndrome: results of phase 3 trials. Journal of Neurodevelopmental Disorders, 9, 3. doi:10.1186/s11689-016-9181-6
   PubMed Web of Science ®Google Scholar
• Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., … Sachar, E. J. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17, 640–655. doi:10.1016/S0002-7138(09)61017-7
   PubMedGoogle Scholar
• Campbell, M., Anderson, L. T., Small, A. M., Adams, P., Gonzalez, N. M., & Ernst, M. (1993). Naltrexone in autistic children: behavioral symptoms and attentional learning. Journal of the American Academy of Child & Adolescent Psychiatry, 32, 1283–1291. doi:10.1097/00004583-199311000-00024
   PubMed Web of Science ®Google Scholar
• Campbell, M., Armenteros, J. L., Malone, R. P., Adams, P. B., Eisenberg, Z. W., & Overall, J. E. (1997). Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 835–843. doi:10.1097/00004583-199706000-00022
   PubMed Web of Science ®Google Scholar
• Chez, M. G., Buchanan, T. M., Becker, M., Kessler, J., Aimonovitch, M. C., & Mrazek, S. R. (2003). Donepezil hydrochloride: A double-blind study in autistic children. Journal of Pediatric Neurology, 01, 083–088. Retrieved from http://hdl.handle.net/1807/1649
   Google Scholar
• Chugani, D. C., Chugani, H. T., Wiznitzer, M., Parikh, S., Evans, P. A., Hansen, R. L., … Hirtz, D. (2016). Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: A randomized trial. The Journal of Pediatrics, 170, 45–53.e4. doi:10.1016/j.jpeds.2015.11.033
   PubMed Web of Science ®Google Scholar
• Cortesi, F., Giannotti, F., Sebastiani, T., Panunzi, S., & Valente, D. (2012). Controlled-release melatonin, singly and combined with cognitive behavioral therapy, for persistent insomnia in children with autism spectrum disorders: A randomized placebo-controlled trial. Journal of Sleep Research, 21, 700–709. doi:10.1111/j.1365-2869.2012.01021.x
   PubMed Web of Science ®Google Scholar
• Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2013). Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. Journal of Autism and Developmental Disorders, 44, 521–531. doi:10.1007/s10803-013-1899-3
   Web of Science ®Google Scholar
• Dean, O. M., Gray, K. M., Villagonzalo, K., Dodd, S., Mohebbi, M., Vick, T., … Berk, M. (2016). A randomized, double-blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian & New Zealand Journal of Psychiatry, 51, 241–249. doi:10.1177/0004867416652735
   PubMed Web of Science ®Google Scholar
• Deutsch, S. I., Urbano, M. R., Neumann, S. A., Burket, J. A., & Katz, E. (2010). Cholinergic abnormalities in autism. Clinical Neuropharmacology, 33, 114–120. doi:10.1097/WNF.0b013e3181d6f7ad
   PubMed Web of Science ®Google Scholar
• Duggal, H. S. (2007). Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. Journal of Child and Adolescent Psychopharmacology, 17, 261–264. doi:10.1089/cap.2006.00136
   PubMed Web of Science ®Google Scholar
• Fankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry, 53, 77–82.
   PubMed Web of Science ®Google Scholar
• Fatemi, S. H., Aldinger, K. A., Ashwood, P., Bauman, M. L., Blaha, C. D., Blatt, G. J., … Welsh, J. P. (2012). Consensus paper: pathological role of the cerebellum in autism. The Cerebellum, 11, 777–807. doi:10.1007/s12311-012-0355-9
   PubMed Web of Science ®Google Scholar
• Feldman, H. M., Kolmen, B. K., & Gonzaga, A. M. (1999). Naltrexone and communication skills in young children with autism. Journal of the American Academy of Child & Adolescent Psychiatry, 38, 587–593. doi:10.1097/00004583-199905000-00021
   PubMed Web of Science ®Google Scholar
• Findling, R. L., Mankoski, R., Timko, K., Lears, K., McCartney, T., McQuade, R. D., … Sheehan, J. J. (2014). A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. The Journal of Clinical Psychiatry, 75, 22–30. doi:10.4088/JCP.13m08500
   PubMed Web of Science ®Google Scholar
• Findling, R. L., McNamara, N. K., Gracious, B. L., O'Riordan, M. A., Reed, M. D., Demeter, C., & Blumer, J. L. (2004). Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 14, 287–294. doi:10.1089/1044546041649129
   PubMed Web of Science ®Google Scholar
• Frye, R. E., Slattery, J., Delhey, L., Furgerson, B., Strickland, T., Tippett, M., … Quadros, E. V. (2018). Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Molecular Psychiatry, 23, 247–256. doi:10.1038/mp.2016.168
   PubMed Web of Science ®Google Scholar
• Gadow, K. D., DeVincent, C. J., & Pomeroy, J. (2006). ADHD symptom subtypes in children with pervasive developmental disorder. Journal of Autism and Developmental Disorders, 36, 271–283. doi:10.1007/s10803-005-0060-3
   PubMed Web of Science ®Google Scholar
• Garstang, J., & Wallis, M. (2006). Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child: Care, Health and Development, 32, 585–589. doi:10.1111/j.1365-2214.2006.00616.x
   PubMed Web of Science ®Google Scholar
• Ghaleiha, A., Asadabadi, M., Mohammadi, M., Shahei, M., Tabrizi, M., Hajiaghaee, R., … Akhondzadeh, S. (2013a). Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. The International Journal of Neuropsychopharmacology, 16, 783–789. doi:10.1017/S1461145712000880
   PubMed Web of Science ®Google Scholar
• Ghaleiha, A., Mohammadi, E., Mohammadi, M., Farokhnia, M., Modabbernia, A., Yekehtaz, H., … Akhondzadeh, S. (2013b). Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: A double-blind, placebo-controlled, randomized trial. Pediatric Drugs, 15, 505–514. doi:10.1007/s40272-013-0036-2
   PubMed Web of Science ®Google Scholar
• Ghanizadeh, A., & Moghimi-Sarani, E. (2013). A randomized double-blind placebo-controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry, 13, 196. doi:10.1186/1471-244X-13-196
   PubMed Web of Science ®Google Scholar
• Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014). A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double-blind clinical trial. Child Psychiatry & Human Development, 45, 185–192. doi:10.1007/s10578-013-0390-x
   PubMed Web of Science ®Google Scholar
• Gringras, P., Nir, T., Breddy, J., Frydman-Marom, A., & Findling, R. L. (2017). Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 56, 948–957.e4. doi:10.1016/j.jaac.2017.09.414
   PubMed Web of Science ®Google Scholar
• Guastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I. B., … Einfeld, S. L. (2014). The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: A randomized controlled trial. Journal of Child Psychology and Psychiatry, 56, 444–452. doi:10.1111/jcpp.12305
   PubMed Web of Science ®Google Scholar
• Handen, B. L., Aman, M. G., Arnold, L. E., Hyman, S. L., Tumuluru, R. V., Lecavalier, L., … Smith, T. (2015). Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 54, 905–915. doi:10.1016/j.jaac.2015.08.013
   PubMed Web of Science ®Google Scholar
• Handen, B. L., Johnson, C. R., McAuliffe-Bellin, S., Murray, P. J., & Hardan, A. Y. (2011). Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology, 21, 43–50. doi:10.1089/cap.2010.0024
   PubMed Web of Science ®Google Scholar
• Hardan, A. Y., Fung, L. K., Libove, R. A., Obukhanych, T. V., Nair, S., Herzenberg, L. A., … Tirouvanziam, R. (2012). A randomized controlled pilot trial of oral n-acetylcysteine in children with autism. Biological Psychiatry, 71, 956–961. doi:10.1016/j.biopsych.2012.01.014
   PubMed Web of Science ®Google Scholar
• Harfterkamp, M., Buitelaar, J. K., Minderaa, R. B., Van de Loo-Neus, G., Van der Gaag, R., & Hoekstra, P. J. (2013). Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: An open-label extension study. Journal of Child and Adolescent Psychopharmacology, 23, 194–199. doi:10.1089/cap.2012.0012
   PubMed Web of Science ®Google Scholar
• Harfterkamp, M., Van de Loo-Neus, G., Minderaa, R. B., Van der Gaag, R., Escobar, R., Schacht, A., … Hoekstra, P. J. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 51, 733–741. doi:10.1016/j.jaac.2012.04.011
   PubMed Web of Science ®Google Scholar
• Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., … Cook, E. H. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15, 682–692. doi:10.1089/cap.2005.15.682
   PubMed Web of Science ®Google Scholar
• Hendren, R. L., James, S. J., Widjaja, F., Lawton, B., Rosenblatt, A., & Bent, S. (2016). Randomized, placebo-controlled trial of methyl b12 for children with autism. Journal of Child and Adolescent Psychopharmacology, 26, 774–783. doi:10.1089/cap.2015.0159
   PubMed Web of Science ®Google Scholar
• Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., … Anagnostou, E. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35, 990–998. doi:10.1038/npp.2009.202
   PubMed Web of Science ®Google Scholar
• Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, R. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582–589. doi:10.1038/sj.npp.1300627
   PubMed Web of Science ®Google Scholar
• Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2006a). Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. The International Journal of Neuropsychopharmacology, 9, 209–213. doi:10.1017/s1461145705005791
   PubMed Web of Science ®Google Scholar
• Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., … Settipani, C. (2012). A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry, 169, 292–299. doi:10.1176/appi.ajp.2011.10050764
   PubMed Web of Science ®Google Scholar
• Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro, M. L., Zagursky, K., & Novotny, S. (2006b). A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology, 16, 541–548. doi:10.1089/cap.2006.16.541
   PubMed Web of Science ®Google Scholar
• Höfer, J., Hoffmann, F., & Bachmann, C. (2016). Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: A systematic review. Autism, 21, 387–402. doi:10.1177/1362361316646559
   PubMed Web of Science ®Google Scholar
• Ichikawa, H., Mikami, K., Okada, T., Yamashita, Y., Ishizaki, Y., Tomoda, A., … Tadori, Y. (2016). Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: A randomized, double-blind, placebo-controlled study. Child Psychiatry & Human Development, 48, 796–806. doi:10.1007/s10578-016-0704-x
   Web of Science ®Google Scholar
• Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S., Aman, M. G., McDougle, C. J., … Posey, D. J. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders, 39, 395–404. doi:10.1007/s10803-008-0636-9
   PubMed Web of Science ®Google Scholar
• Jaselskis, C. A., Cook, E. H., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322–327. doi:10.1097/00004714-199210000-00005
   PubMed Web of Science ®Google Scholar
• Ji, N. Y., & Findling, R. L. (2015). An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Current Opinion in Psychiatry, 28, 91–101. doi:10.1097/yco.0000000000000132
   PubMed Web of Science ®Google Scholar
• Karvat, G., & Kimchi, T. (2014). Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism. Neuropsychopharmacology, 39, 831–840. doi:10.1038/npp.2013.274
   PubMed Web of Science ®Google Scholar
• Kent, J. M., Kushner, S., Ning, X., Karcher, K., Ness, S., Aman, M., … Hough, D. (2013). Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. Journal of Autism and Developmental Disorders, 43, 1773–1783. doi:10.1007/s10803-012-1723-5
   PubMed Web of Science ®Google Scholar
• King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., … Ritz, L. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Archives of General Psychiatry, 66, 583–590. doi:10.1001/archgenpsychiatry.2009.30
   PubMed Web of Science ®Google Scholar
• King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., Mcmahon, W., … Cook, E. H. (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 658–665. doi:10.1097/00004583-200106000-00010
   PubMed Web of Science ®Google Scholar
• Klaiman, C., Huffman, L., Masaki, L., & Elliott, G. R. (2013). Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology, 23, 320–328. doi:10.1089/cap.2012.0127
   PubMed Web of Science ®Google Scholar
• Kosaka, H., Okamoto, Y., Munesue, T., Yamasue, H., Inohara, K., Fujioka, T., … Wada, Y. (2016). Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial. Translational Psychiatry, 6, e872. doi:10.1038/tp.2016.152
   PubMed Web of Science ®Google Scholar
• Lee, D. O., & Ousley, O. Y. (2006). Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16, 737–746. doi:10.1089/cap.2006.16.737
   PubMed Web of Science ®Google Scholar
• Lee, M., Martin-Ruiz, C., Graham, A., Court, J., Perry, R., Iversen, P., … Perry, E. (2002). Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain, 125, 1483–1495. doi:https://doi.org/10.1093/brain/awf160 doi:10.1093/brain/awf160
   PubMed Web of Science ®Google Scholar
• Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., … Ben-Ari, Y. (2012). A randomised controlled trial of bumetanide in the treatment of autism in children. Translational Psychiatry, 2, e202. doi:10.1038/tp.2012.124
   PubMed Web of Science ®Google Scholar
• Lemonnier, E., Villeneuve, N., Sonie, S., Serret, S., Rosier, A., Roue, M., … Ben-Ari, Y. (2017). Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Translational Psychiatry, 7, e1124. doi:10.1038/tp.2017.101
   PubMed Web of Science ®Google Scholar
• Loebel, A., Brams, M., Goldman, R. S., Silva, R., Hernandez, D., Deng, L., … Findling, R. L. (2016). Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders, 46, 1153–1163. doi:10.1007/s10803-015-2628-x
   PubMed Web of Science ®Google Scholar
• Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S., & Delaney, M. A. (2001). Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 887–894. doi:10.1097/00004583-200108000-00009
   PubMed Web of Science ®Google Scholar
• Malone, R. P., Delaney, M. A., Hyman, S. B., & Cater, J. R. (2007). Ziprasidone in adolescents with autism: an open-label pilot study. Journal of Child and Adolescent Psychopharmacology, 17, 779–790. doi:10.1089/cap.2006.0126
   PubMed Web of Science ®Google Scholar
• Mankad, D., Dupuis, A., Smile, S., Roberts, W., Brian, J., Lui, T., … Anagnostou, E. (2015). A randomized, placebo-controlled trial of omega-3 fatty acids in the treatment of young children with autism. Molecular Autism, 6, 18. doi:10.1186/s13229-015-0010-7
   PubMed Web of Science ®Google Scholar
• Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 48, 1110–1119. doi:10.1097/CHI.0b013e3181b76658
   PubMed Web of Science ®Google Scholar
• Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., … Findling, R. L. (2011). Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder. The Journal of Clinical Psychiatry, 72, 1270–1276. doi:10.4088/JCP.09m05933
   PubMed Web of Science ®Google Scholar
• Martin, A., Koenig, K., Scahill, L., & Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 9, 99–107. doi:10.1089/cap.1999.9.99
   PubMed Web of Science ®Google Scholar
• McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., … McMahon, D. (2002). Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med, 347, 314–321. doi:10.1056/NEJMoa013171
   PubMed Web of Science ®Google Scholar
• McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001. doi:10.1001/archpsyc.1996.01830110037005
   PubMed Web of Science ®Google Scholar
• McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., … Vitiello, B. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162, 1142–1148. doi:10.1176/appi.ajp.162.6.1142
   PubMed Web of Science ®Google Scholar
• Minshawi, N. F., Wink, L. K., Shaffer, R., Plawecki, M. H., Posey, D. J., Liu, H., … Erickson, C. A. (2016). A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism, 7, 2. doi:10.1186/s13229-015-0062-8
   PubMed Web of Science ®Google Scholar
• Mohammadi, M., Yadegari, N., Hassanzadeh, E., Farokhnia, M., Yekehtaz, H., Mirshafiee, O., & Akhondzadeh, S. (2013). Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism. Clinical Neuropharmacology, 36, 179–184. doi:10.1097/WNF.0b013e3182a9339d
   PubMed Web of Science ®Google Scholar
• Moreno-Fuenmayor, H., Borjas, L., Arrieta, A., Valera, V., & Socorro-Candanoza, L. (1996). Plasma excitatory amino acids in autism. Investigación Clínica, 37, 113–128.
   PubMedGoogle Scholar
• Ooi, Y., Weng, S., Kossowsky, J., Gerger, H., & Sung, M. (2016). Oxytocin and autism spectrum disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry, 50, 5–13. doi:10.1055/s-0042-109400
   PubMed Web of Science ®Google Scholar
• Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., … Findling, R. L. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540. doi:10.1542/peds.2008-3782
   PubMed Web of Science ®Google Scholar
• Owen-Smith, A. A., Bent, S., Lynch, F. L., Coleman, K. J., Yau, V. M., Pearson, K. A., … Croen, L. A. (2015). Prevalence and predictors of complementary and alternative medicine use in a large insured sample of children with autism spectrum disorders. Research in Autism Spectrum Disorders, 17, 40–51. doi:10.1016/j.rasd.2015.05.002
   PubMed Web of Science ®Google Scholar
• Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37, 367–373. doi:10.1007/s10803-006-0234-7
   PubMed Web of Science ®Google Scholar
• Panksepp, J., & Sahley, T. L. (1987). Possible brain opioid involvement in disrupted social intent and language development of autism. In: Neurobiological Issues in Autism, Current issues in autism (pp. 357–372). Boston, MA: Springer.
   Google Scholar
• Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., … Hardan, A. Y. (2017). Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proceedings of the National Academy of Sciences, 114, 8119–8124. doi:10.1073/pnas.1705521114
   PubMed Web of Science ®Google Scholar
• Pearson, D. A., Santos, C. W., Aman, M. G., Arnold, L. E., Casat, C. D., Mansour, R., … Cleveland, L. A. (2013). Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent Psychopharmacology, 23, 337–351. doi:10.1089/cap.2012.0096
   PubMed Web of Science ®Google Scholar
• Perry, E. K., Lee, M. L., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., Merrit, J., … Wenk, G. L. (2001). Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. American Journal of Psychiatry, 158, 1058–1066. doi:10.1176/appi.ajp.158.7.1058
   PubMed Web of Science ®Google Scholar
• Purcell, A. E., Jeon, O. H., Zimmerman, A. W., Blue, M. E., & Pevsner, J. (2001). Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology, 57, 1618–1628. doi:10.1212/WNL.57.9.1618
   PubMed Web of Science ®Google Scholar
• Reichow, B. (2012). Overview of meta-analyses on early intensive behavioral intervention for young children with autism spectrum disorders. Journal of Autism and Developmental Disorders, 42, 512–520. doi:10.1007/s10803-011-1218-9
   PubMed Web of Science ®Google Scholar
• Remington, G., Sloman, L., Konstantareas, M., Parker, K., & Gow, R. (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology, 21, 440–444. doi:10.1097/00004714-200108000-00012
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology Autism Network (RUPP) (2005a). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62, 1266. doi:10.1001/archpsyc.62.11.1266
   PubMedGoogle Scholar
• Research Units on Pediatric Psychopharmacology Autism Network (RUPP). (2005b). Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry, 162, 1361–1369. doi:10.1176/appi.ajp.162.7.1361
   PubMed Web of Science ®Google Scholar
• Roy, A., Roy, M., Deb, S., Unwin, G., & Roy, A. (2014). Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: A systematic review. Journal of Intellectual Disability Research, 59, 293–306. doi:10.1111/jir.12122
   PubMed Web of Science ®Google Scholar
• Saad, K., Abdel-Rahman, A. A., Elserogy, Y. M., Al-Atram, A. A., El-Houfey, A. A., Othman, H. A., … Abdel-Salam, A. M. (2016). Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder. Journal of Child Psychology and Psychiatry, 59, 20–29. doi:10.1111/jcpp.12652
   PubMed Web of Science ®Google Scholar
• Saad, K., Eltayeb, A. A., Mohamad, I. L., Al-Atram, A. A., Elserogy, Y., Bjørklund, G., … Nicholson, B. (2015). A randomized, placebo-controlled trial of digestive enzymes in children with autism spectrum disorders. Clinical Psychopharmacology and Neuroscience, 13, 188–193. doi:10.9758/cpn.2015.13.2.188
   PubMed Web of Science ®Google Scholar
• Sandman, C. A., & Kemp, A. S. (2011). Opioid antagonists may reverse endogenous opiate “dependence” in the treatment of self-injurious behavior. Pharmaceuticals, 4, 366–381. doi:10.3390/ph4020366
   Google Scholar
• Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., & Politte, L. (2015). Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. American Journal of Psychiatry, 172, 1197–1206. doi:10.1176/appi.ajp.2015.15010055
   PubMed Web of Science ®Google Scholar
• Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641. doi:10.1542/peds.2003-0264-f
   PubMed Web of Science ®Google Scholar
• Singh, K., Connors, S. L., Macklin, E. A., Smith, K. D., Fahey, J. W., Talalay, P., & Zimmerman, A. W. (2014). Sulforaphane treatment of autism spectrum disorder (ASD). Proceedings of the National Academy of Sciences, 111, 15550–15555. doi:10.1073/pnas.1416940111
   PubMed Web of Science ®Google Scholar
• Smith, T., Aman, M. G., Arnold, L. E., Silverman, L. B., Lecavalier, L., Hollway, J., … Handen, B. L. (2016). Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. Journal of the American Academy of Child & Adolescent Psychiatry, 55, 868–876.e2. doi:10.1016/j.jaac.2016.06.015
   PubMed Web of Science ®Google Scholar
• Van IJzendoorn, M. H., & Bakermans-Kranenburg, M. J. (2012). A sniff of trust: Meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology, 37, 438–443. doi:10.1016/j.psyneuen.2011.07.008
   PubMed Web of Science ®Google Scholar
• Veenstra-VanderWeele, J., Cook, E. H., King, B. H., Zarevics, P., Cherubini, M., Walton-Bowen, K., … Carpenter, R. L. (2016). Arbaclofen in children and adolescents with autism spectrum disorder: A randomized, controlled, phase 2 trial. Neuropsychopharmacology, 42, 1390–1398. doi:10.1038/npp.2016.237
   PubMed Web of Science ®Google Scholar
• Virues-Ortega, J., Julio, F. M., & Pastor-Barriuso, R. (2013). The TEACCH program for children and adults with autism: A meta-analysis of intervention studies. Clinical Psychology Review, 33, 940–953. doi:10.1016/j.cpr.2013.07.005
   PubMed Web of Science ®Google Scholar
• Voigt, R. G., Mellon, M. W., Katusic, S. K., Weaver, A. L., Matern, D., Mellon, B., … Barbaresi, W. J. (2014). A randomized, double-blind, placebo-controlled trial of dietary docosahexaenoic acid (dha) supplementation in children with autism. Journal of Pediatric Gastroenterology and Nutrition, 58, 715–722. doi:10.1097/MPG.0000000000000260
   PubMed Web of Science ®Google Scholar
• Wasdell, M. B., Jan, J. E., Bomben, M. M., Freeman, R. D., Rietveld, W. J., Tai, J., … Weiss, M. D. (2008). A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. Journal of Pineal Research, 44, 57–64. doi:10.1111/j.1600-079x.2007.00528.x
   PubMed Web of Science ®Google Scholar
• Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., … Hollander, E. (2006). Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology, 21, 363–367. doi:10.1097/01.yic.0000224787.13782.0f
   PubMed Web of Science ®Google Scholar
• Wink, L. K., Adams, R., Wang, Z., Klaunig, J. E., Plawecki, M. H., Posey, D. J., … Erickson, C. A. (2016). A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Molecular Autism, 7, 26. doi:10.1186/s13229-016-0088-6
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). (2017, April). Autism spectrum disorders. Retrieved from http://www.who.int/mediacentre/factsheets/autism-spectrum-disorders/en/
   Google Scholar
• Wright, B., Sims, D., Smart, S., Alwazeer, A., Alderson-Day, B., Allgar, V., … Miles, J. (2011). Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behavior management strategies: A randomized controlled crossover trial. Journal of Autism and Developmental Disorders, 41, 175–184. doi:10.1007/s10803-010-1036-5
   PubMed Web of Science ®Google Scholar
• Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2015). The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial. Molecular Psychiatry, 21, 1225–1231. doi:10.1038/mp.2015.162
   PubMed Web of Science ®Google Scholar